Loading companies…
S
Science4Beauty
Poland · Biotech
A Polish skincare company using a recombinant conotoxin active ingredient in anti-wrinkle creams and other products sold directly to consumers and through aesthetic-medicine channels.
A recombinant peptide in topical skincare
Science4Beauty makes Miorelaxant Magic anti-wrinkle creams and related skincare products. Its proprietary active ingredient is a recombinant conotoxin peptide inspired by compounds found in cone-snail venom; the company produces it in E. coli rather than harvesting it from animals. The topical formula is designed to relax facial-expression muscles and reduce the appearance of wrinkles, while remaining a cosmetic product rather than an injectable treatment.
A marketed product with clinical evaluation
The company sells its products online and says it began sales through aesthetic-medicine clinics after completing the cosmetic registration process in 2023. It also presents a randomized, double-blind study involving 60 volunteers that compared a conotoxin cream with a placebo after botulinum-toxin treatment over six months. This places Science4Beauty beyond laboratory development, with a commercial skincare range and clinical evaluation of its lead product.
- Headquarters
- Warsaw, Poland
- Product
- Conotoxin-based skincare and cosmeceuticals
- Commercial status
- Products registered and on sale since 2023
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | PLN 7M | 4growth VC — LeadHard2beat — LeadBusiness angels — Participant |
Investors
4growth VCLed Series AHard2beatLed Series ABusiness angelsJoined Series ACoverage
Sep 3, 2026Science4Beauty · Series ASimilar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
ATAptadir TherapeuticsRNA therapeutics designed to restore expression of silenced genes€40M · Seed